Ironwood Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Ironwood Financial’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-3	Closed	–	–	446
2014 Q4	$0	Buy	+3	New	+$338	﹤0.01%	407

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ironwood Financial's VRTX Position: Q1 2015 in Review

Ironwood Financial sold out of Vertex Pharmaceuticals (VRTX) in Q1 2015, closing a stake of 3 shares.

Ironwood Financial first reported a position in VRTX in Q4 2014 and held it in 1 quarter. The position peaked at $0 in Q4 2014. 480 funds tracked by Wall St. Rank hold VRTX as of Q1 2015.

Ironwood Financial reported no remaining Vertex Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Ironwood Financial sold 3 Vertex Pharmaceuticals shares in Q1 2015.
Ironwood Financial first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 1 quarter.
Ironwood Financial's Vertex Pharmaceuticals position peaked at $0 in Q4 2014.
480 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2015.

Based on Ironwood Financial's 13F filing for Q1 2015, filed 6 May 2015.